According to Sarepta Therapeutics 's latest financial reports the company's current revenue (TTM) is $1.24 B. In 2022 the company made a revenue of $0.93 B an increase over the years 2021 revenue that were of $0.70 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.24 B | 33.26% |
2022 | $0.93 B | 32.93% |
2021 | $0.70 B | 29.96% |
2020 | $0.54 B | 41.82% |
2019 | $0.38 B | 26.51% |
2018 | $0.30 B | 94.74% |
2017 | $0.15 B | 2751.58% |
2016 | $5.42 M | 332.64% |
2015 | $1.25 M | -87.16% |
2014 | $9.75 M | -31.38% |
2013 | $14.21 M | -61.91% |
2012 | $37.32 M | -20.56% |
2011 | $46.99 M | 59.72% |
2010 | $29.42 M | 67.27% |
2009 | $17.58 M | -17.26% |
2008 | $21.25 M | 93.52% |
2007 | $10.98 M | 9428.23% |
2006 | $0.11 M | -97.59% |
2005 | $4.78 M | 1011.31% |
2004 | $0.43 M | -55.62% |
2003 | $0.96 M | 15.9% |
2002 | $0.83 M | 18.51% |
2001 | $0.7 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $27.11 B | 2,080.83% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | $0.93 B | -24.57% | ๐บ๐ธ USA |
Novavax NVAX | $0.69 B | -44.23% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $1.82 B | 47.05% | ๐บ๐ธ USA |
Insmed INSM | $0.30 B | -75.45% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.33 B | -73.34% | ๐บ๐ธ USA |
Avidity Biosciences RNA | $9.56 M | -99.23% | ๐บ๐ธ USA |